Data Science, AI, and Machine Learning in Drug Development

Herausgegeben:Yang, Harry

• Gebundenes Buch

Produktbeschreibung

The confluence of big data, artificial intelligence (AI), and machine learning (ML) has led to a paradigm shift in how innovative medicines are developed and healthcare delivered. To fully capitalize on these technological advances, it is essential to systematically harness data from diverse sources and leverage digital technologies and advanced analytics to enable data-driven decisions. Data science stands at a unique moment of opportunity to lead such a transformative change.

Intended to be a single source of information, Data Science, AI, and Machine Learning in Drug Research and Development covers a wide range of topics on the changing landscape of drug R & D, emerging applications of big data, AI and ML in drug development, and the build of robust data science organizations to drive biopharmaceutical digital transformations.

Features
Provides a comprehensive review of challenges and opportunities as related to the applications of big data, AI, and ML in the entire spectrum of drug R & DDiscusses regulatory developments in leveraging big data and advanced analytics in drug review and approvalOffers a balanced approach to data science organization buildPresents real-world examples of AI-powered solutions to a host of issues in the lifecycle of drug developmentAffords sufficient context for each problem and provides a detailed description of solutions suitable for practitioners with limited data science expertise

Produktdetails

• Chapman & Hall/CRC Biostatistics Series
• Verlag: Chapman and Hall/CRC / Taylor & Francis
• Seitenzahl: 320
• Erscheinungstermin: 3. Oktober 2022
• Englisch
• Abmessung: 237mm x 165mm x 25mm
• Gewicht: 620g
• ISBN-13: 9780367708078
• ISBN-10: 0367708078
• Artikelnr.: 64104867

Autorenporträt

Harry Yang, Ph.D., is the Vice President and Head of Biometrics at Fate Therapeutics. He has 27 years of experience across all aspects of drug R & D, from early target discovery, through pre-clinical, clinical, translational science, and CMC programs to regulatory approval and post-approval lifecycle management. He played a pivotal role in the successful submissions of 5 biologics license appllications (BLAs) that ultimately led to marketing approvals of five biological products. He has published 8 statistical and data science books, 28 book chapters, over 100 peer-reviewed articles, and 3 industry white papers on diverse scientific, statistical, and data science subjects. He is a frequent invited speaker at national and international conferences. He has also developed statistical courses and conducted trainings at the United States Food and Drug Administration (FDA) and United States Pharmacopeia (USP).

Inhaltsangabe

1 Transforming Pharma with Data Science, AI and Machine Learning 2 Regulatory Perspective on Big Data, AI, and Machining Learning 3 Building an Agile and Scalable Data Science Organization 4 AI and Machine Learning in Drug Discovery 5 Predicting Anti-Cancer Synergistic Activity Through Machine Learning and Natural Language Processing 6 AI-Enabled Clinical Trials 7 Machine Learning for Precision Medicine 8 Reinforcement Learning in Personalized Medicine 9 Leveraging Machine Learning, Natural Language Processing, and Deep Learning in Drug Safety and Pharmacovigilance 10 Intelligent Manufacturing and Supply of Biopharmaceuticals 11 Reinventing Medical Affairs in the Era of Big Data and Analytics 12 Deep Learning with Electronic Health Record 13 Real-World Evidence for Treatment Access and Payment Decisions

Rezensionen

"The book offers a beautiful journey to explore the application of AI and ML in DrugDevelopment. Even though it cannot replace academic courses in AI, ML andhealthcare,authors provide very important and interesting updates regarding the evolution andadvances achieved in this field the past 10 years."

Ramzi El Feghali, ISCB News, May 2024.